{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:09:42Z","timestamp":1748578182519,"version":"3.41.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.brachy.2021.02.007","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T04:54:08Z","timestamp":1616820848000},"page":"701-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of brachytherapy in stage III endometrial cancer treated with adjuvant chemotherapy: Identifying factors predictive of a survival benefit"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0170-9321","authenticated-orcid":false,"given":"Michael","family":"Xiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana P.","family":"English","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2021.02.007_bib0001","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.3802\/jgo.2020.31.e39","article-title":"Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma","volume":"31","author":"Xiang","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0002","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ygyno.2018.12.007","article-title":"National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma","volume":"152","author":"Xiang","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0003","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.brachy.2021.02.007_bib0004","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.prro.2014.01.003","article-title":"The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline","volume":"4","author":"Klopp","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): Patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0006","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.brachy.2021.02.007_bib0007","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2019.06.020","article-title":"Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma","volume":"154","author":"Xiang","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: Adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer","author":"Randall","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0009","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.adro.2015.10.001","article-title":"An analysis of appropriate delivery of postoperative radiation therapy for endometrial cancer using the RAND\/UCLA Appropriateness Method: Executive summary","volume":"1","author":"Jones","year":"2016","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0010","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0011","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ijrobp.2016.12.035","article-title":"Brachytherapy improves survival in stage III endometrial cancer with cervical involvement","volume":"97","author":"Bingham","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"year":"2020","series-title":"National Comprehensive Cancer Network","key":"10.1016\/j.brachy.2021.02.007_bib0012"},{"key":"10.1016\/j.brachy.2021.02.007_bib0013","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0014","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ygyno.2016.04.010","article-title":"The role of adjuvant radiation in lymph node positive endometrial adenocarcinoma","volume":"141","author":"Shaikh","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijrobp.2007.05.048","article-title":"Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: A SEER registry analysis","volume":"70","author":"Rossi","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.02.007_bib0016","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0360-3016(01)01566-8","article-title":"Significant pelvic recurrence in high-risk pathologic stage I\u2013IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy","volume":"50","author":"Mundt","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.02.007_bib0017","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2012.10.010","article-title":"A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer","volume":"128","author":"Secord","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0018","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/IGC.0000000000000376","article-title":"Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics","volume":"25","author":"Young","year":"2015","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.brachy.2021.02.007_bib0019","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.brachy.2021.02.007_bib0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-8258(03)00126-4","article-title":"Survival after relapse in patients with endometrial cancer: results from a randomized trial","volume":"89","author":"Creutzberg","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0021","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.3802\/jgo.2018.29.e49","article-title":"Value of combined adjuvant chemotherapy and radiation on survival for stage III uterine cancer: Is less radiation equal to more?","volume":"29","author":"Wang","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0022","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2015.62.5459","article-title":"Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline","volume":"33","author":"Meyer","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0023","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2014.06.003","article-title":"Endometrial cancer: A review and current management strategies: part II","volume":"134","author":"Burke","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.brachy.2021.02.007_bib0024","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472121000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472121000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:12:23Z","timestamp":1748545943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472121000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1538472121000441"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2021.02.007","relation":{},"ISSN":["1538-4721"],"issn-type":[{"type":"print","value":"1538-4721"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of brachytherapy in stage III endometrial cancer treated with adjuvant chemotherapy: Identifying factors predictive of a survival benefit","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2021.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}